Recent Visitors
Matthew Myrvik PhDMatthew Myrvik PhD
Joseph S. Goveas MDJoseph S. Goveas MD
Beth A. Erickson MDBeth A. Erickson MD
Carolyn A. Taylor PhDCarolyn A. Taylor PhD
Scott P. Levick PhDScott P. Levick PhD

Colleen A. Lawton MD Online Profile

Colleen A. Lawton MD

Professor
Medical College of Wisconsin
Department: Radiation Oncology
Program: Clinical


Publications

  • Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413. (Cury FL, Hunt D, Roach M 3rd, Shipley W, Gore E, Hsu IC, Krisch RE, Seider MJ, Sandler H, Lawton C) Cancer 2013 Mar 15: PMID 23504930
  • Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. (Gay HA, Barthold HJ, O'Meara E, Bosch WR, El Naqa I, Al-Lozi R, Rosenthal SA, Lawton C, Lee WR, Sandler H, Zietman A, Myerson R, Dawson LA, Willett C, Kachnic LA, Jhingran A, Portelance L, Ryu J, Small W Jr, Gaffney D, Viswanathan AN, Michalski JM) Int J Radiat Oncol Biol Phys 2012 Jul 1;83(3):e353-62 PMID 22483697
  • A research agenda for radiation oncology: results of the radiation oncology institute's comprehensive research needs assessment. (Jagsi R, Bekelman JE, Brawley OW, Deasy JO, Le QT, Michalski JM, Movsas B, Thomas CR Jr, Lawton CA, Lawrence TS, Hahn SM) Int J Radiat Oncol Biol Phys 2012 Oct 1;84(2):318-22 PMID 22436790
  • Impact of computed tomography image quality on image-guided radiation therapy based on soft tissue registration. (Morrow NV, Lawton CA, Qi XS, Li XA) Int J Radiat Oncol Biol Phys 2012 Apr 1;82(5):e733-8 PMID 22349041
  • Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate. (Lawton CA, Yan Y, Lee WR, Gillin M, Firat S, Baikadi M, Crook J, Kuettel M, Morton G, Sandler H) Int J Radiat Oncol Biol Phys 2012 Apr 1;82(5):e795-801 PMID 22330999
  • Mitigation of late renal and pulmonary injury after hematopoietic stem cell transplantation. (Cohen EP, Bedi M, Irving AA, Jacobs E, Tomic R, Klein J, Lawton CA, Moulder JE) Int J Radiat Oncol Biol Phys 2012 May 1;83(1):292-6 PMID 22104363
  • Consolidating risk estimates for radiation-induced complications in individual patient: late rectal toxicity. (Prior P, Devisetty K, Tarima SS, Lawton CA, Semenenko VA) Int J Radiat Oncol Biol Phys 2012 May 1;83(1):53-63 PMID 22024204
  • Development of an online adaptive solution to account for inter- and intra-fractional variations. (Li XA, Liu F, Tai A, Ahunbay E, Chen G, Kelly T, Lawton C, Erickson B) Radiother Oncol 2011 Sep;100(3):370-4 PMID 21924781
  • Validation of an online replanning technique for prostate adaptive radiotherapy. (Peng C, Chen G, Ahunbay E, Wang D, Lawton C, Li XA) Phys Med Biol 2011 Jun 21;56(12):3659-68 PMID 21610293
  • Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05). (Lawton CA, Hunt D, Lee WR, Gomella L, Grignon D, Gillin M, Morton G, Pisansky TM, Sandler H) Int J Radiat Oncol Biol Phys 2011 Sep 1;81(1):1-7 PMID 21470793
  • Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of radiation therapy oncology group trials. (Hamstra DA, Bae K, Pilepich MV, Hanks GE, Grignon DJ, McGowan DG, Roach M, Lawton C, Lee RJ, Sandler H) Int J Radiat Oncol Biol Phys 2011 Dec 1;81(5):1293-301 PMID 21458924
  • Evaluation of nuclear factor κB and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610. (Okera M, Bae K, Bernstein E, Cheng L, Lawton C, Wolkov H, Pollack A, Dicker A, Sandler H, Sweeney CJ) BJU Int 2011 Jul;108(2 Pt 2):E51-8 PMID 21156016
  • Characterizing interfraction variations and their dosimetric effects in prostate cancer radiotherapy. (Peng C, Ahunbay E, Chen G, Anderson S, Lawton C, Li XA) Int J Radiat Oncol Biol Phys 2011 Mar 1;79(3):909-14 PMID 20732764
  • Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials. (Rodrigues G, Bae K, Roach M, Lawton C, Donnelly B, Grignon D, Hanks G, Porter A, Lepor H, Sandler H) Int J Radiat Oncol Biol Phys 2011 Jun 1;80(2):445-52 PMID 20615632
  • To treat pelvic nodes or not? Greater testicular scatter does not explain the results of randomized trials. (Roach M 3rd, Lawton CA, Chen J) J Clin Oncol 2010 Sep 1;28(25):e450-2 PMID 20567007
  • Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer. (Roach M 3rd, Bae K, Lawton C, Donnelly BJ, Grignon D, Hanks GE, Porter A, Lepor H, Venketesan V, Sandler H) Int J Radiat Oncol Biol Phys 2010 Dec 1;78(5):1314-22 PMID 20378270
  • Online adaptive replanning method for prostate radiotherapy. (Ahunbay EE, Peng C, Holmes S, Godley A, Lawton C, Li XA) Int J Radiat Oncol Biol Phys 2010 Aug 1;77(5):1561-72 PMID 20362401
  • Follicular lymphoma transformation to dual translocated Burkitt-like lymphoma: improved disease control associated with radiation therapy. (Parker SM, Olteanu H, Vantuinen P, Lawton CA, Schultz CJ, Christians KK, Fenske TS) Int J Hematol 2009 Dec;90(5):616-22 PMID 19937165
  • Results of the Association of Directors of Radiation Oncology Programs (ADROP) survey of radiation oncology residency program directors. (Harris EE, Abdel-Wahab M, Spangler AE, Lawton CA, Amdur RJ) Int J Radiat Oncol Biol Phys 2009 Jun 1;74(2):327-37 PMID 19427549
  • Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. (Michalski JM, Lawton C, El Naqa I, Ritter M, O'Meara E, Seider MJ, Lee WR, Rosenthal SA, Pisansky T, Catton C, Valicenti RK, Zietman AL, Bosch WR, Sandler H, Buyyounouski MK, Ménard C) Int J Radiat Oncol Biol Phys 2010 Feb 1;76(2):361-8 PMID 19394158
  • ACR appropriateness criteria on external beam radiation therapy treatment planning for clinically localized prostate cancer expert panel on radiation oncology--prostate. (Michalski JM, Roach M 3rd, Merrick G, Anscher MS, Beyer DC, Lawton CA, Lee WR, Pollack A, Rosenthal SA, Vijayakumar S, Carroll PR) Int J Radiat Oncol Biol Phys 2009 Jul 1;74(3):667-72 PMID 19386445
  • Hypofractionation for prostate cancer. (Ritter M, Forman J, Kupelian P, Lawton C, Petereit D) Cancer J 2009 Jan-Feb;15(1):1-6 PMID 19197165
  • A comparison of daily megavoltage CT and ultrasound image guided radiation therapy for prostate cancer. (Peng C, Kainz K, Lawton C, Li XA) Med Phys 2008 Dec;35(12):5619-28 PMID 19175119
  • RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. (Lawton CA, Michalski J, El-Naqa I, Buyyounouski MK, Lee WR, Menard C, O'Meara E, Rosenthal SA, Ritter M, Seider M) Int J Radiat Oncol Biol Phys 2009 Jun 1;74(2):383-7 PMID 18947938
  • Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer. (Lawton CA, Michalski J, El-Naqa I, Kuban D, Lee WR, Rosenthal SA, Zietman A, Sandler H, Shipley W, Ritter M, Valicenti R, Catton C, Roach M 3rd, Pisansky TM, Seider M) Int J Radiat Oncol Biol Phys 2009 Jun 1;74(2):377-82 PMID 18947941
  • An on-line replanning scheme for interfractional variations. (Ahunbay EE, Peng C, Chen GP, Narayanan S, Yu C, Lawton C, Li XA) Med Phys 2008 Aug;35(8):3607-15 PMID 18777921
  • Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. (Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU) J Clin Oncol 2008 May 20;26(15):2497-504 PMID 18413638
  • Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of radiation therapy oncology group protocol 9413. (Taussky D, Bae K, Bahary JP, Roach M 3rd, Lawton CA, Shipley WU, Sandler HM) Urology 2008 Nov;72(5):1125-9 PMID 18314175
  • Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. (Roach M 3rd, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich MV) J Clin Oncol 2008 Feb 1;26(4):585-91 PMID 18172188
  • Pelvic lymph node irradiation for prostate cancer: who, why, and when? (Wang D, Lawton C) Semin Radiat Oncol 2008 Jan;18(1):35-40 PMID 18082586
  • Designing equivalent treatment regimens for prostate radiotherapy based on equivalent uniform dose. (Li XA, Wang JZ, Stewart RD, Dibiase SJ, Wang D, Lawton CA) Br J Radiol 2008 Jan;81(961):59-68 PMID 18039721
  • Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02. (Lawton CA, Bae K, Pilepich M, Hanks G, Shipley W) Int J Radiat Oncol Biol Phys 2008 Feb 1;70(2):437-41 PMID 17881145
  • Adjuvant androgen deprivation therapy augments cure and long-term cancer control in men with poor prognosis, nonmetastatic prostate cancer. (Fleshner N, Keane TE, Lawton CA, Mulders PF, Payne H, Taneja SS, Morris T) Prostate Cancer Prostatic Dis 2008;11(1):46-52 PMID 17607304
  • An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. (Lawton CA, DeSilvio M, Roach M 3rd, Uhl V, Kirsch R, Seider M, Rotman M, Jones C, Asbell S, Valicenti R, Hahn S, Thomas CR Jr) Int J Radiat Oncol Biol Phys 2007 Nov 1;69(3):646-55 PMID 17531401
  • A descriptive analysis of postimplant dosimetric parameters from Radiation Therapy Oncology Group P0019. (Lee WR, Bae K, Lawton CA, Gillin MT, Morton G, Firat S, Baikadi M, Kuettel M, Greven K, Sandler H) Brachytherapy 2006 Oct-Dec;5(4):239-43 PMID 17118317
  • Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05). (Lawton CA, DeSilvio M, Lee WR, Gomella L, Grignon D, Gillin M, Morton G, Pisansky T, Sandler H) Int J Radiat Oncol Biol Phys 2007 Jan 1;67(1):39-47 PMID 17084551
  • Quality assurance methods for the first Radiation Therapy Oncology Group permanent prostate implant protocol. (Gillin MT, Dunning BF, Lawton CA, Foley WD, Byhardt RW, Morton G, Baikadi M, Pisansky TT, Michalski JM, Ibbott G, Lopez F, Radiation Therapy Oncology Group) Brachytherapy 2006 Jul-Sep;5(3):152-6 PMID 16864066
  • Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10. (Shipley WU, Desilvio M, Pilepich MV, Roach M 3rd, Wolkov HB, Sause WT, Rubin P, Lawton CA) Int J Radiat Oncol Biol Phys 2006 Mar 15;64(4):1162-7 PMID 16427211
  • Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. (Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D) Int J Radiat Oncol Biol Phys 2005 Apr 1;61(5):1285-90 PMID 15817329
  • Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer. (Li XA, Wang JZ, Jursinic PA, Lawton CA, Wang D) Int J Radiat Oncol Biol Phys 2005 Mar 15;61(4):1251-7 PMID 15752907
  • Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. (Lawton CA, Winter K, Grignon D, Pilepich MV) J Clin Oncol 2005 Feb 1;23(4):800-7 PMID 15681524
  • Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. (Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, Venkatesan V, Lawton CA, Roach M 3rd, Shipley WU, Hanks GE, Sandler HM) J Clin Oncol 2004 Jun 1;22(11):2133-40 PMID 15169799
  • Hormones and radiation therapy in locally advanced adenocarcinoma of the prostate. (Lawton CA) Semin Radiat Oncol 2003 Apr;13(2):141-51 PMID 12728443
  • Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610. (Pollack A, Grignon DJ, Heydon KH, Hammond EH, Lawton CA, Mesic JB, Fu KK, Porter AT, Abrams RA, Shipley WU) J Clin Oncol 2003 Apr 1;21(7):1238-48 PMID 12663710
  • Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10. (Shipley WU, Lu JD, Pilepich MV, Heydon K, Roach M, Wolkov HB, Sause WT, Rubin P, Lawton CA, Machtay M) Int J Radiat Oncol Biol Phys 2002 Dec 1;54(5):1302-10 PMID 12459350
  • Loss of renal function following bone marrow transplantation: an analysis of angiotensin converting enzyme D/I polymorphism and other clinical risk factors. (Juckett MB, Cohen EP, Keever-Taylor CA, Zheng Y, Lawton CA, Moulder JE, Klein J) Bone Marrow Transplant 2001 Feb;27(4):451-6 PMID 11313676
  • Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. (Horwitz EM, Winter K, Hanks GE, Lawton CA, Russell AH, Machtay M) Int J Radiat Oncol Biol Phys 2001 Mar 15;49(4):947-56 PMID 11240235
  • Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. (Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, Coughlin CT, Pilepich MV) Int J Radiat Oncol Biol Phys 2001 Mar 15;49(4):937-46 PMID 11240234
  • Prostatic carcinoma. (Lawton CA, Grignon D, Newhouse JH, Schellhammer PF, Kuban DA) Radiographics 1999 Jan-Feb;19(1):185-203 PMID 9925399
  • Long-term results of selective renal shielding in patients undergoing total body irradiation in preparation for bone marrow transplantation. (Lawton CA, Cohen EP, Murray KJ, Derus SW, Casper JT, Drobyski WR, Horowitz MM, Moulder JE) Bone Marrow Transplant 1997 Dec;20(12):1069-74 PMID 9466280
  • Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Radiation Therapy Oncology Group. (Lawton CA, Winter K, Byhardt R, Sause WT, Hanks GE, Russell AH, Rotman M, Porter A, McGowan DG, DelRowe JD, Pilepich MV) Int J Radiat Oncol Biol Phys 1997 Jul 15;38(5):931-9 PMID 9276357
  • Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. (Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, Porter A, Shipley WU, Grignon D) J Clin Oncol 1997 Mar;15(3):1013-21 PMID 9060541
  • p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. (Grignon DJ, Caplan R, Sarkar FH, Lawton CA, Hammond EH, Pilepich MV, Forman JD, Mesic J, Fu KK, Abrams RA, Pajak TF, Shipley WU, Cox JD) J Natl Cancer Inst 1997 Jan 15;89(2):158-65 PMID 8998185
  • Recombinant human interferon-beta (rHuIFN-beta) and radiation therapy for inoperable non-small cell lung cancer. (Byhardt RW, Vaickus L, Witt PL, Chang AY, McAuliffe T, Wilson JF, Lawton CA, Breitmeyer J, Alger ME, Borden EC) J Interferon Cytokine Res 1996 Nov;16(11):891-902 PMID 8938564
  • Results of a phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer (RTOG Protocol 90-20). (Lawton CA, Coleman CN, Buzydlowski JW, Forman JD, Marcial VA, DelRowe JD, Rotman M) Int J Radiat Oncol Biol Phys 1996 Oct 1;36(3):673-80 PMID 8948352
  • Pulmonary function changes in long-term survivors of bone marrow transplantation. (Gore EM, Lawton CA, Ash RC, Lipchik RJ) Int J Radiat Oncol Biol Phys 1996 Aug 1;36(1):67-75 PMID 8823260
  • Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. (Pilepich MV, Krall JM, al-Sarraf M, John MJ, Doggett RL, Sause WT, Lawton CA, Abrams RA, Rotman M, Rubin P) Urology 1995 Apr;45(4):616-23 PMID 7716842
  • Bone marrow transplant nephropathy: radiation nephritis revisited. (Cohen EP, Lawton CA, Moulder JE) Nephron 1995;70(2):217-22 PMID 7566307
  • PSA screening. (Wilson JF, Hussey DH, Lawton CA, Leibel SA, Shipley WU) J Fam Pract 1994 Sep;39(3):216-7 PMID 7521388
  • Prostate cancer: are racial differences in clinical stage and survival explained by differences in symptoms? (Lawton CA, Cantrell JE, Derus SW, Murray KJ, Byhardt RW, Wilson JF) Radiology 1994 Jul;192(1):37-40 PMID 8208961
  • Effect of nephrotoxic drugs on the development of radiation nephropathy after bone marrow transplantation. (Lawton CA, Fish BL, Moulder JE) Int J Radiat Oncol Biol Phys 1994 Mar 1;28(4):883-9 PMID 8138441
  • Clinical course of late-onset bone marrow transplant nephropathy. (Cohen EP, Lawton CA, Moulder JE, Becker CG, Ash RC) Nephron 1993;64(4):626-35 PMID 8366991
  • Is long-term survival possible with external beam irradiation for stage D1 adenocarcinoma of the prostate? (Lawton CA, Cox JD, Glisch C, Murray KJ, Byhardt RW, Wilson JF) Cancer 1992 Jun 1;69(11):2761-6 PMID 1571906
  • Influence of renal shielding on the incidence of late renal dysfunction associated with T-lymphocyte deplete bone marrow transplantation in adult patients. (Lawton CA, Barber-Derus SW, Murray KJ, Cohen EP, Ash RC, Moulder JE) Int J Radiat Oncol Biol Phys 1992;23(3):681-6 PMID 1612975
  • Twice-daily tapering dexamethasone treatment during cranial radiation for newly diagnosed brain metastases. (Weissman DE, Janjan NA, Erickson B, Wilson FJ, Greenberg M, Ritch PS, Anderson T, Hansen RM, Chitambar CR, Lawton CA) J Neurooncol 1991 Dec;11(3):235-9 PMID 1726656
  • Allogeneic bone marrow transplantation for relapsed and refractory lymphoma using genotypically HLA-identical and alternative donors. (Lundberg JH, Hansen RM, Chitambar CR, Lawton CA, Gottlieb M, Anderson T, Ash RC) J Clin Oncol 1991 Oct;9(10):1848-59 PMID 1919635
  • Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. (Lawton CA, Won M, Pilepich MV, Asbell SO, Shipley WU, Hanks GE, Cox JD, Perez CA, Sause WT, Doggett SR) Int J Radiat Oncol Biol Phys 1991 Sep;21(4):935-9 PMID 1917622
  • Late renal dysfunction in adult survivors of bone marrow transplantation. (Lawton CA, Cohen EP, Barber-Derus SW, Murray KJ, Ash RC, Casper JT, Moulder JE) Cancer 1991 Jun 1;67(11):2795-800 PMID 2025844
  • Technical modifications in hyperfractionated total body irradiation for T-lymphocyte deplete bone marrow transplant. (Lawton CA, Barber-Derus S, Murray KJ, Casper JT, Ash RC, Gillin MT, Wilson JF) Int J Radiat Oncol Biol Phys 1989 Aug;17(2):319-22 PMID 2666364
  • Extended-field radiation therapy for prostatic carcinoma with para-aortic lymph node metastasis. (Lawton CA, Glisch C, Byhardt RW, Sehring S, Hartz A, Cox JD) Am J Clin Oncol 1986 Aug;9(4):302-6 PMID 3751968